Related Experiment Videos

Targeting the RB-pathway in cancer therapy

Erik S Knudsen1, Jean Y J Wang

  • 1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 11, 2010
PubMed

Insights

The RB-pathway regulates cell cycle and death; its disruption in cancer offers therapeutic targets. Targeting RB-pathway defects can improve cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The RB-pathway, involving cyclin-dependent kinases, retinoblastoma tumor suppressor (RB), and E2F transcription factors, is crucial for cell cycle control and apoptosis.
  • Alterations in RB-pathway components like p16Ink4a, cyclin D1, and RB are common in human cancers, driving uncontrolled cell proliferation.

Purpose of the Study:

  • To explore the therapeutic potential of targeting RB-pathway defects in cancer.
  • To discuss how RB-pathway status influences responses to various cancer therapies.

Main Methods:

  • Literature review and analysis of existing research on the RB-pathway in cancer.
  • Discussion of the impact of RB-pathway alterations on cellular responses to cytotoxic, cytostatic, and hormone therapies.

Main Results:

  • RB-pathway disruptions are frequent in sporadic human cancers, promoting deregulated proliferation.
  • Understanding RB-pathway status is key to predicting responses to existing cancer therapies.

Conclusions:

  • Exploiting tumor-specific RB-pathway defects presents opportunities for novel cancer therapeutic strategies.
  • Directly targeting RB-pathway components offers a promising avenue for cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...